Chronic pain is a rising health problem that is predicted to affect up to 30% of adults worldwide, but current treatments -such as opioids and non-steroidal antiinflammatory drugs (NSAIDs) -are inadequate 1 . Chronic pain comprises several different types of pain, including inflammatory pain following tissue injury (for example, arthritis) 2,3 , cancer pain 4, 5 , and neuropathic pain following nerve injury, spinal cord injury and brain injury (for example, stroke and trauma) [6] [7] [8] [9] . Chronic pain is typically characterized by hyperalgesia, which is an increased response to noxious thermal and mechanical stimuli as well as allodynia, in which nociceptive responses occur to normally innocuous stimuli such as light touch (known as mechanical allodynia). Neuropathic pain is also characterized by burning pain, paraesthesia (a sensation of tingling, tickling, prickling and pricking) and dysaesthesia (an unpleasant, abnormal sense of touch).
. Chronic pain is typically characterized by hyperalgesia, which is an increased response to noxious thermal and mechanical stimuli as well as allodynia, in which nociceptive responses occur to normally innocuous stimuli such as light touch (known as mechanical allodynia). Neuropathic pain is also characterized by burning pain, paraesthesia (a sensation of tingling, tickling, prickling and pricking) and dysaesthesia (an unpleasant, abnormal sense of touch).
It is generally understood that chronic pain results from altered neuronal activity (that is, neuronal plasticity). This altered activity includes the sensitization of peripheral primary sensory neurons in the dorsal root ganglia and trigeminal ganglia [10] [11] [12] and the sensitization of central nociceptive neurons in the spinal cord, trigeminal nucleus, brain stem and cortex 13, 14 . These actions in the peripheral nervous system (PNS), known as peripheral sensitization, and central nervous system (CNS), known as central sensitization, mean that an individual has a heightened perception of pain.
Pain is one of the cardinal features of inflammation.
It is well established that inflammatory mediators that are released locally after tissue injury can directly stimulate and cause sensitization of pain-sensing nociceptors located at nerve fibres of primary afferent neurons in peripheral tissues 10 (FIG. 1) ; these locally released inflammatory mediators include classic mediators (for example, bradykinin, prostaglandins, H + , ATP and nerve growth factor), pro-inflammatory cytokines and chemokines, as well as emerging mediators such as bacterial N-formylated peptides 15 and microRNAs 16 . Therefore, acute inflammation is intimately linked to the development of acute pain.
Hyperactivity of primary sensory neurons following peripheral inflammation will also increase the release of neurotransmitters (for example, glutamate) and neuromodulators, such as substance P, calcitonin gene-related peptide (CGRP) and brain-derived neurotrophic factor (BDNF), from the central terminals of primary afferent neurons in the spinal cord and trigeminal nucleus, causing hyperactivity of postsynaptic nociceptive neurons -that is, central sensitization 17 . In particular, central sensitization is responsible for the secondary pain outside the initial injury site 17, 18 . Activation of NMDA (N-methyl-daspartate) receptors and mitogen-activated protein kinases (MAPKs) has an important role in central sensitization and pain hypersensitivity [19] [20] [21] . Although acute inflammation produces transient central sensitization, chronic pain is associated with a long-lasting and sometimes even permanent central
Mechanical allodynia
A painful response to a normally innocuous mechanical stimulation. It is also regarded as a cardinal feature of chronic pain.
Trigeminal ganglia
The location of cell bodies of primary sensory neurons, including nociceptive and touch neurons that innervate the orofacial area.
Emerging targets in neuroinflammationdriven chronic pain Nature Reviews | Drug Discovery , ATP, nerve growth factors (NGFs), pro-inflammatory cytokines (tumour necrosis factor (TNF; formerly known as TNFα), interleukin-1β (IL-1β) and IL-6) and pro-inflammatory chemokines (CC-chemokine ligand 2 (CCL2), CXC-chemokine ligand 1 (CXCL1) and CXCL5). Nociceptor neurons express the receptors for all of these inflammatory mediators, which act on their respective receptors on peripheral nociceptor nerve fibres. These receptors include G protein-coupled receptors (GPCRs), ionotropic receptors, and tyrosine kinase receptors, and their activation results in the generation of second messengers such as Ca 2+ and cyclic AMP, which in turn activate several kinases, such as protein kinase A (PKA), PKC, calcium/calmodulin-dependent protein kinase (CaMK), phosphoinositide 3-kinase (PI3K) and the mitogen-activated protein kinases (MAPKs) extracellular signal-regulated kinase (ERK), p38 MAPK and JUN N-terminal kinase (JNK). Activation of these kinases causes hypersensitivity and hyperexcitability of nociceptor neurons (known as peripheral sensitization) through the modulation of key transduction molecules such as transient receptor potential cation channel subfamily A member 1 (TRPA1), TRPV1 and Piezo (a stretch-activated ion channel), as well as key conduction molecules such as the voltage-gated sodium channels Nav1.7, Nav1.8 and Nav1.9. Nociceptor neurons also express Toll-like receptors (TLRs; specifically, TLR3, TLR4 and TLR7), which can be activated by exogenous ligands (known as pathogen-activated molecular patterns, which include viral and bacterial components) and endogenous ligands (known as danger-activated molecular patterns, such as RNAs). Certain microRNAs (for example, let-7b) serve as novel pain mediators to activate nociceptors via TLR7, which is coupled to TRPA1 (the coupling is further enhanced when TLR7 is activated by let-7b). Bacterial infection with Staphylococcus aureus also directly activates nociceptors and induces neuronal hyperexcitability by releasing bacterial N-formylated peptides (FPs) and the formation of the pore-forming toxin α-haemolysin (α-HL). Activation of nociceptors also releases substance P and calcitonin gene-related peptide (CGRP), which are involved in the generation of neurogenic inflammation. CGRP also negatively regulates lymphadenopathy after inflammation. 4-HNE, 4-hydroxynonenal; 5,6-EET, 5,6-epoxyeicosatrienoic acid; ASIC, acid-sensing ion channel; FPR1, formyl peptide receptor 1; HETE, 5-hydroxyeico satetraenoic acid; HMGB1, high mobility group protein B1; P2X3, P2X purinergic receptor 3; PGE 2 , prostaglandin E 2 ; RTK, receptor tyrosine kinase.
Trigeminal nucleus
A collection of cell bodies located in the brainstem that receive sensory inputs from the orofacial area.
Inflammation
A biological response of vascular tissue to harmful stimuli, such as tissue injury, infection or irritants. The classical signs of acute inflammation -which is protective and promotes healing -are pain, heat, redness, swelling and loss of function.
Primary afferent neurons
Sensory neurons that carry sensory information from the periphery to the central nervous system.
Chemokines
A family of about 50 small, secreted cytokines that act on G protein-coupled receptors. They can be classified into four subfamilies: the C family, the CC family, the CXC family and the CX3C family.
Primary sensory neurons
Neurons with cell bodies located in the dorsal root and trigeminal ganglia. Their peripheral terminals innervate skin and muscle and their central axons terminate in the spinal cord and trigeminal nucleus.
Mitogen-activated protein kinases
(MAPKs). The MAPK family consists of extracellular signal-regulated kinase 1 (ERK1), ERK2, p38 MAPK, JUN N-terminal kinase (JNK) and ERK5, and is activated by phosphorylation. MAPKs have important roles in intracellular signalling in neurons and glia and in the genesis of pain hypersensitivity.
Neuroinflammation
Local inflammation in the peripheral and central nervous system, which is more efficient at driving chronic pain than systemic inflammation.
sensitization that persists after acute inflammation has been resolved 22 . For example, Toll-like receptor 4 (TLR4) expressed in the spinal cord was shown to mediate the transition from acute to persistent mechanical hypersensitivity after the resolution of inflammation in a rodent model of arthritis 22 . Pain and inflammation can also be dissociated in other conditions; for example, periodontal disease (which occurs as a result of chronic inflammation) is not normally associated with pain.
Recent progress indicates that the development of neuroinflammation -inflammation of tissue within the PNS and CNS -is responsible for generating and sustaining the sensitization of nociceptive neurons 23, 24 that leads to chronic pain. Therefore, targeting the processes and molecules that are involved in neuroinflammation could lead to better treatments for chronic pain.
As well as having a key role in the development of chronic pain, increasing evidence suggests that neuroinflammation is an underlying cause of several CNS diseases, including Alzheimer's disease, Parkinson's disease, multiple sclerosis and psychiatric disorders 25 . However, there is controversy as to whether neuroinflammation has a detrimental or beneficial role in the pathology of CNS diseases 26, 27 , depending on whether pro-inflammatory mediators (which will be detrimental) versus anti-inflammatory mediators and/or growth factors (which will be beneficial) are produced at different stages of neuroinflammation. Of note, there are clear differences between CNS neuroinflammation in neurodegenerative diseases and that in chronic pain after peripheral injury
.
Neuroinflammation occurs in the PNS (that is, peripheral nerves and ganglia) and CNS (that is, the spinal cord and brain) and is characterized by infiltration of leukocytes and increased production of inflammatory mediators at these sites. The trafficking of different types of leukocytes in the PNS and CNS has distinct temporal profiles; the initial trafficking of neutrophils (which occurs within hours) is followed by trafficking of macrophages (which occurs within days) and then by the infiltration of T cells (which takes days to weeks) 28, 29 . In particular, neuro inflammation manifests as the activation of glial cells -such as Schwann cells -in the nerve, satellite glial cells in the ganglia and microglia, and astrocytes and oligodendrocytes in the spinal cord and brain 30 . Activation of glial cells leads to the production of glial mediators that can modulate pain sensitivity 31 . Of the cells that are resident in the CNS, microglia are probably the first to respond (within days) to peripheral nerve damage, followed by astrocytes (which respond within days to weeks) [32] [33] [34] . These temporal details are relevant to drug targeting for controlling the initiation and maintenance of chronic pain, because the cell types and hence mediators will differ depending on the stage of chronic pain that a drug can target. In addition, an increase in the permeability of the blood-brain barrier and the blood-spinal cord barrier (BSCB) -which leads to increased leukocyte invasion to the CNS -is an important feature of CNS inflammation.
Neuroinflammation is a local form of inflammation, which means that it is more effective at eliciting and sustaining pain than systemic inflammation, yet it is difficult to detect in the clinic. For example, fibromyalgia, a chronic muscle pain condition, was previously regarded as an atypical form of pain because no obvious pathologies and inflammation could be detected in affected patients. However, a recent study identified neuropathy of small nerve fibres in patients with fibromyalgia 35 , which could be a result as well as a cause of chronic neuroinflammation. Neuroinflammation appears to be permanent in patients with chronic pain; for example, neuroinflammation (measured by glial activation and cytokine expression) was positively associated with neuropathic pain in postmortem spinal cord samples taken from HIV-infected patients 36 . Neuroinflammation in the CNS could also be neurogenic inflammation 37 , as it can be triggered by neuronal activities from primary sensory neurons 38, 39 or local neurons in the spinal cord.
There are several excellent reviews on peripheral neuroinflammation and chronic pain 30, 40 . In this Review we focus on how central neuroinflammation drives chronic pain (FIG. 2) , in part because central inflammation produces more targets to sustain chronic pain. We outline how the production of inflammatory and glial mediators in the spinal cord modulates synaptic transmission to provide a link between neuroinflammation and chronic
Box 1 | Neuroinflammation in neurodegenerative diseases and in chronic pain
There are clear differences between central nervous system (CNS) neuroinflammation in neurodegenerative diseases (for example, Alzheimer's disease) and that in chronic pain following peripheral injury. Neuroinflammation in neurodegenerative diseases and spinal cord injury is a result of direct damage to the CNS and will cause further neuronal degeneration and cell death (that is, secondary injury) 25 . In chronic pain (namely neuropathic and inflammatory pain), neuroinflammation is often due to peripheral damage and excessive neuronal activity of primary sensory neurons. Therefore, CNS neuroinflammation after peripheral injury is relatively mild and does not cause marked neuronal loss 161, 162 . There are also differences in the roles of pro-inflammatory cytokines in neurodegenerative disease compared to inflammatory pain. Cytokines such as tumour necrosis factor (TNF; formerly known as TNFα) and interleukin-1β (IL-1β) cause neurodegeneration and impair memory and synaptic plasticity (such as long-term potentiation) in several regions of the brain (for example, the hippocampus and dentate gyrus) that are associated with brain dysfunction in neurodegenerative disease 163, 164 . By contrast, TNF and IL-1β serve as neuromodulators in the spinal cord dorsal horn after peripheral injury and induce or enhance synaptic plasticity (for example, long-term potentiation) as well as inflammatory and neuropathic pain 66, 165, 166 . Of interest, neutralization of TNF has been shown to inhibit chronic pain in patients with rheumatoid arthritis much faster than it improves the signs of inflammation (such as a reduction in joint swelling), probably by inhibiting TNF-mediated nociceptive neurotransmission (synaptic plasticity) in the spinal cord dorsal horn before the improvement of inflammation 167 . Nature Reviews | Drug Discovery This neuroinflammation is triggered by activity-dependent release of glial activators (that is, neurotransmitters, chemokines and proteases, as well as WNT ligands) from the central terminals of primary afferent neurons and/or by disruption of the blood-brain barrier (BBB). Neuroinflammation is characterized by the activation of microglia and astrocytes, the infiltration of immune cells to the peripheral nervous system (PNS; for example, the dorsal root ganglia (DRG)) and the central nervous system (CNS; for example, the spinal cord), and the production of inflammatory and glial mediators such as pro-inflammatory cytokines and chemokines, as well as growth factors and gliotransmitters (that is, glutamate and ATP). These glial mediators can powerfully modulate excitatory and inhibitory synaptic transmission, leading to central sensitization and enhanced chronic pain states. Glial mediators can further act on glial and immune cells to facilitate neuroinflammation via autocrine and paracrine routes. Furthermore, neuroinflammation generates anti-inflammatory cytokines and pro-resolution lipid mediators (PRLMs) to normalize neuroinflammation, synaptic plasticity and abnormal chronic pain. AMPAR, AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptor; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; CCL2, CC-chemokine ligand 2; CX3CL1, CX3C-chemokine ligand 1; CXCL1, CXC-chemokine ligand 1; ERK, extracellular signal-regulated kinase; GABAR, GABA (γ-aminobutyric acid) receptor; GlyR, glycine receptor; IFNγ, interferon-γ; IL-1β, interleukin-1β; JNK, JUN N-terminal kinase; MAPK, mitogen-activated protein kinase; MMP9, matrix metalloproteinase 9; NMDAR, NMDA (N-methyl-d-aspartate) receptor; TGFβ, transforming growth factor-β; TNF, tumour necrosis factor; tPA, tissue-type plasminogen activator. pain, and highlight emerging targets -including chemokines -that mediate interactions between neurons and glial cells, lipid mediators that act on neurons and glia to resolve inflammation, as well as other emerging targets that modulate neuroinflammation, such as proteases and WNT signalling molecules. In addition, we highlight the advantages and disadvantages of each approach. We focus on these targets for two main reasons: first, because these are relatively new targets in the field of pain research; and second, because they modulate chronic pain via a unique mechanism -that is, neuron-glia interactions in the CNS.
Glial activation

Dorsal root ganglion (DRG
Infiltration of immune cells in the CNS.
Infiltration of leukocytes such as macrophages and T cells into the spinal cord is very obvious after direct injury to the spinal cord (such as spinal cord contusion) 27 . Immune cell infiltration into the CNS after peripheral nerve injury or tissue injury is also evident. Activation of CC-chemokine receptor 2 (CCR2) contributes to the infiltration of bone marrow-derived macrophages into the spinal cord after peripheral nerve injury 41 . T cell infiltration in the spinal cord was also implicated in the development of neuropathic pain after nerve injury, in an age-dependent manner 28 . Opening of the BSCB has been reported after nerve injury and C-fibre activation in rodents, leading to immune cell infiltration to the spinal cord 42, 43 .
Activation of microglia and astrocytes in chronic pain.
Owing to the presence of larger numbers of residential glial cells compared to leukocytes, residential glial cells are thought to have a more important role in the development of chronic pain. So-called 'glial activation' is emerging as a key mechanism underlying the genesis of chronic pain 31 . Notably, glia have more than one activation state, and they may still be active even in the physiological resting state 44 . Thus, it is important to define the specific characteristics of activated glia that can be associated with their different activation states
. Each activation state of glia might have a distinct set of characteristics and glia with these characteristics may have different roles in pain sensitization; therefore, some characteristics and/or activation states would be more appropriate for therapeutic targeting than others 31, 45 . Tumour necrosis factor (TNF; formerly known as TNFα) is one of the most studied and potent inflammatory cytokines and has been shown to be expressed by microglia, astrocytes and primary sensory dorsal root ganglion (DRG) neurons 46, 47 . However, single-cell PCR analysis reveals that although the majority of microglia (90%) and some astrocytes (40%) express TNF, neurons of the spinal cord do not express it 48 , which suggests that microglia are the major source of TNF in the spinal cord. Interleukin-1β (IL-1β), another crucial inflammatory cytokine, is expressed by both microglia and astrocytes in the spinal cord 49, 50 , whereas IL-18 -which is closely related to IL-1β -is induced in microglia after nerve injury and chronic opioid exposure 51, 52 . Chemokines such as CC-chemokine ligand 2 (CCL2; also known as MCP1), CXC-chemokine ligand 1 (CXCL1; also known as a keratinocyte-derived chemokine) and CCL7 are produced in spinal cord astrocytes to facilitate neuropathic pain [53] [54] [55] . BDNF was originally found in DRG neurons and their spinal cord central terminals 56 
, but it
Box 2 | Distinct characteristics of activated glia
Glia can be referred to as activated and non-activated, although even under the resting state microglia are still undertaking surveillance functions. As the characteristics of activated glia vary, this suggests that different activation states of glia may exist.
Gliosis (also known as glial hypertrophy or the glial reaction) is the most investigated characteristic of activated glia and manifests as changes in glial morphology and the upregulation of glial markers such as CD11B and ionized calcium binding adaptor molecule 1 (IBA1) on microglia, and glial fibrillary acidic protein (GFAP) and S100 on astrocytes [168] [169] [170] . It appears that astrocytic hypertrophy in the spinal cord is more general and persistent than microglial hypertrophy and better correlated with chronic pain states following several pain injuries 31, 33, 171 . Notably, microglial hypertrophy in the spinal cord that is induced by nerve injury is age dependent; neuropathic pain and microglial reaction do not occur in young rats (<3 weeks old) 172 . Activation of mitogen-activated protein kinases (MAPKs) is another prominent characteristic of glial activation. Extracellular signal-regulated kinase 1 (ERK1), ERK2, p38 MAPK, JUN N-terminal kinase (JNK) and ERK5 are involved in intracellular signalling in activated glia and in the pathogenesis of chronic pain 173 . Strikingly, different MAPKs have distinct activation patterns in spinal glial cells after nerve injury, such as p38 MAPK and ERK5 activation in microglia, JNK activation in astrocytes, and the sequential activation of ERK1 and ERK2 in microglia and then in astrocytes [174] [175] [176] . Nerve injury also causes upregulation of many receptors and channels in glia in rodent models. Peripheral nerve injury induces the expression of the ATP receptors P2X purinergic receptor 4 (P2X4), P2X7, P2Y6 and P2Y12 in spinal microglia, which is implicated in the development of neuropathic pain 87, [177] [178] [179] [180] . Connexin-43 hemichannels, which control ATP release 181 , are upregulated in spinal cord astrocytes after spinal cord injury and are also involved in the development of neuropathic pain 182 . Furthermore, CX3C-chemokine receptor 1 (CX3CR1) is specifically expressed in microglia and is upregulated in the spinal cord after nerve injury 183 . Neuropathic pain is also associated with downregulation of the glutamate transporters GLT1 (also known as SLC1A2) and GLAST (also known as SLC1A3) in spinal cord astrocytes, which causes a deficit in glutamate clearance from synaptic clefts and the extracellular space, leading to enhanced glutamatergic transmission 31, 184 . The generation of glial mediators is the characteristic of activated glia that is most crucial for their role in pain regulation. Glial mediators powerfully modulate excitatory and inhibitory synaptic transmission in the spinal cord 31, 153, 185 .
C-fibres
Small-diameter unmyelinated afferent nerve fibres that have low conduction velocity and carry sensory pain information from the periphery to the central nervous system. They can be activated by capsaicin, an ingredient that gives rise to the hot sensation caused by eating chilli peppers.
Anion reversal potential
The membrane potential at which there is no net flow of a particular anion ion (Cl − ) from one side of the membrane to the other. After nerve injury, a decrease in the Cl − anion reversal potential (a shift to less negative potentials) reduces glycine and/or GABA A (γ-aminobutyric acid type A) receptor-mediated hyperpolarization, leading to the genesis of neuropathic pain.
Gate control mechanism
A mechanism proposed by Ronald Melzack and Patrick Wall during the early 1960s, which suggests that the spinal cord dorsal horn contains a neural circuit that undergoes excitatory and inhibitory modulation that serves as a gate that either allows or blocks the transmission of pain signals to the brain.
is also induced in spinal microglia after nerve injury and following chronic morphine treatment, and it contributes to neuropathic pain and morphine tolerance 57, 58 . Basic fibroblast growth factor is induced in spinal cord astrocytes to sustain neuropathic pain 59 . Furthermore, glial cells produce anti-inflammatory cytokines such as IL-4, IL-10, transforming growth factor-β (TGFβ) and interferon-α (IFNα) to antagonize pain 26, 31, 60, 61 , but the cellular localization of these anti-inflammatory cytokines is not well characterized.
Nerve injury also causes proliferation of microglia 62 and astrocytes 63 in the spinal cord, which could contribute to increased production of glial mediators and the expression of hyperalgesia and allodynia. Glial mediators are neuromodulators, and as such they can powerfully modulate synaptic transmission in the spinal cord at nanomolar concentrations. Of interest, TNF, IL-1β, IL-6 and BDNF modulate both excitatory and inhibitory synaptic transmission 24, 57, 64, 65 . In the dorsal horn, TNF increases glutamate release from the terminals of C-fibres that express transient receptor potential cation channel subfamily V member 1 (TRPV1), leading to enhanced excitatory synaptic transmission in excitatory interneurons in lamina IIo, which in turn synapse to lamina-I projection neurons to form a pain circuit 66 . BDNF secreted from microglia induces a transsynaptic reduction in the expression of the electroneutral potassium-chloride co-transporter 2 (KCC2; also known as SLC12A5), leading to a depolarizing shift in the anion reversal potential in projection neurons in lamina I. As a result, GABA (γ-aminobutyric acid) produces less inhibition and sometimes even evokes excitation in spinal cord projection neurons 57, 58 . Dis-inhibition of GABAergic and glycinergic synaptic transmission in the spinal cord pain circuitry has an important role in generating chronic pain 57, 67 . Interestingly, a feedforward glycinergic circuit in the laminae II-III of the spinal cord was implicated as a new gate control mechanism for pain, and loss of this gate control after nerve injury opens the gate to enable normally innocuous mechanical stimulation to elicit mechanical allodynia -a cardinal feature of neuropathic pain 68 . Although many of the above-mentioned molecules, such as TNF, IL-1β, IL-6 and KCC2, are potential targets for pain therapeutics, this Review focuses on emerging targets (TABLE 1) that have both pro-and antiinflammatory actions. We also discuss new therapeutic strategies for chronic pain management, in which targets with anti-inflammatory actions should be activated or potentiated, and targets with pro-inflammatory actions should be reduced or blocked.
Chemokines: mediators of neuron-glia signalling It is generally believed that neuroinflammation modulates chronic pain by promoting signalling interactions between neurons and glial cells 31, 45, 69, 70 . In particular, chemokines are well positioned to mediate these interactions because the chemokines and their receptors are differentially expressed in neurons and glial cells. Chemokine-mediated neuron-glia interactions are bidirectional. First, neurons express chemokines, and glial cells express the respective receptors of these chemokines. Second, glial cells express chemokines, and neurons express their respective receptors 23 . The role of chemokines in the regulation of peripheral leukocyte migration and activation, cell adhesion and T cell activation, as well as in the induction of peripheral sensitization, is well established 40, 71 . Here we focus on the role of chemokines within the CNS in the processing of chronic pain, and provide an update on recent progress in this research area. Specifically, we discuss several pairs of chemokines and their receptors in modulating signalling from neurons to glia, and from glia to neurons in the spinal cord, and address how this signalling is involved in the persistence of chronic pain.
CX3CL1 and CX3CR1 mediate neuron-microglia inter actions. CX3C-chemokine ligand 1 (CX3CL1; also known as fractalkine) is the only member of CX3C subfamily and has two distinct molecular forms: a membrane-bound form that promotes cell adhesion and a soluble form with chemotactic properties. CX3CL1 is constitutively expressed in DRG and spinal cord neurons 72, 73 . Following nerve injury in a rodent model or treatment of DRG neurons with the protease cathepsin S, CX3CL1 is cleaved and secreted from DRG neurons (including from their central terminals) and spinal neurons 73 . It then binds to CX3C-chemokine receptor 1 (CX3CR1), which is the only receptor of CX3CL1 and, importantly, is specifically expressed in microglia and upregulated in chronic pain conditions 72, 74 . Neuropathic pain is reduced by the spinal administration of a CX3CR1-neutralizing antibody in rats, and is abrogated in Cx3cr1-knockout mice [73] [74] [75] . Mechanistically, CX3CL1 was shown to activate p38 MAPK in spinal microglia 74 . Thus, CX3CL1 and CX3CR1 are involved in neuronmicroglia interactions in the spinal cord to promote chronic pain. In addition to the neutralizing antibody mentioned above, a human CX3CL1 analogue (named F1) was identified as the first CX3CR1 antagonist that could potently inhibit macrophage accumulation in a murine model of periodontitis 76 . The analgesic efficacy of this antagonist needs to be tested in animal models.
CCL2 and CCR2 mediate neuron-microglia and astrocyteneuron interactions. CCL2 is one of 28 members of the CC subfamily of chemokines. CCL2 recognizes several receptors, including CCR1, CCR2 and CCR4, but CCR2 is the preferred receptor with higher affinity for CCL2 (REFS 23, 40) . CCL2 neutralization, CCR2 antagonists or deletion of Ccr2 all reduce neuropathic pain in rodents 41, 54, 77, 78 . Early studies suggested that CCL2 and CCR2 are involved in signalling interactions between primary sensory neurons and microglia in the spinal cord in neuropathic pain, based on the following evidence: first, nerve injury causes upregulation of CCL2 in DRG nociceptor neurons 29 . Second, high-intensity stimulation of the dorsal root (which contains efferent fibres of DRG neurons) induces the release of CCL2 from spinal cord slices taken from animal models of neuropathic pain 69 . Third, Ccr2-knockout mice have reduced levels of neuropathic pain and spinal microgliosis 41, 45, 78 . However, there is insufficient morphological evidence
Spinal nerve ligation
A form of nerve injury that is used to induce long-lasting neuropathic pain in rodents.
for CCR2 expression in spinal microglia 77 , although CCR2 was shown to be upregulated in microglia in the rostral ventromedial medulla (an area of the brainstem that is involved in pain modulation) following spinal nerve ligation in rats 79 . Recent studies (published from 2009 onwards) indicate that CCL2 and CCR2 also mediate astrocyte-neuron signalling in the spinal cord during neuropathic pain. First, nerve injury in mice induces the expression of CCL2 astrocytes in the spinal cord and trigeminal nucleus, and also upregulates CCR2 in spinal cord neurons 54, 80 . Second, incubation of spinal cord slices with CCL2 very rapidly (within minutes) increases excitatory synaptic transmission, NMDA currents and extracellular signal-regulated kinase (ERK) activation in dorsal horn neurons 54 . Third, transgenic mice overexpressing CCL2 in astrocytes are hypersensitive to pain 81 . Thus, CCL2 also serves as a neuromodulator in the spinal cord. It is reasonable to postulate that CCL2-and CCR2-mediated neuron-microglia interactions (which activate microglia in the early phase of nerve injury) are involved in the induction of neuropathic pain, and CCL2-and CCR2-mediated astrocyte-neuron signalling (which is delayed and sustained) is involved in the maintenance of neuropathic pain.
CXCL1 and CXCR2 mediate astrocyte-neuron inter actions. CXCL1 belongs to the CXC family of chemokines. CXCL1 in rodents has similar biological roles as IL-8 in humans. Spinal nerve ligation in mice induces a persistent increase in CXCL1 expression in spinal cord astrocytes (lasting longer than 3 weeks); this increase can also be recapitulated by the application of TNF in astrocyte cultures 55 . CXCL1 is also selectively expressed in hypertrophic astrocytes from active multiple sclerosis lesions taken from patients 82 , which indicates a possible involvement of astrocytic CXCL1 in the pathogenesis of multiple sclerosis. CXC-chemokine receptor 2 (CXCR2), the major receptor of CXCL1 (REF. 40 ), is upregulated in dorsal horn neurons after nerve injury. Behavioural studies showed that intrathecal injection of a CXCL1-neutralizing antibody or the CXCR2 antagonist SB225002 attenuated mechanical allodynia and heat hyperalgesia that were induced by spinal nerve ligation in mice. Moreover, intraspinal delivery of CXCL1 short hairpin RNA (shRNA) via lentivirus produced similar effects 55 . These data suggest that CXCL1-CXCR2 signalling, which mediates astrocyte-neuron interactions, has an important role in the maintenance of neuropathic pain. In addition, CXCL1 may be involved in other types of cell-cell signalling, as it is transiently induced in DRG neurons after nerve injury (which can be involved in neuron-microglia signalling in the same way as CCL2) 83 . After spinal cord injury, spinal cord astrocytes also express CXCL1, which promotes the entry of leukocytes to the site of injury 84 .
Other chemokines involved in pain modulation. The expression of CCL21 (also known as secondary lymphoid tissue chemokine) in neurons after spinal cord or nerve injury in rodents was implicated in microglial activation in the thalamus and spinal cord 85, 86 . Injection of recombinant CCL21 into the ventral posterolateral nucleus of the thalamus transiently activated microglia and induced pain-related behaviours in rats, and these effects could be blocked by the non-selective microglial inhibitor minocycline 85 . Another study showed that the development of allodynia was blocked in CCL21-deficient mice or following the intrathecal administration of a CCL21-blocking antibody to wild-type mice. Furthermore, the nerve injury-induced upregulation of P2X purinergic receptor 4 (P2X4) in microglia, which is essential for the development of neuropathic pain in rats 87 , was also abolished in CCL21-deficient mice 86 . In mice, nerve injury also induces a long-lasting upregulation of CCL7 in spinal cord astrocytes to sustain neuropathic pain, and intrathecal administration of a CCL7-neutralizing antibody suppressed nerve injuryinduced spinal microglia activation and neuropathic pain-like behaviour 53 . CXCL12 (also known as SDF1) and its receptor CXCR4 are involved in neuron-glia signalling in DRG neurons and HIV-associated peripheral neuropathy; in rats, treatment with the CXCR4 antagonist plerixafor (Mozobil; Genzyme (previously known as AMD3100)) inhibited the pain hypersensitivity produced by an antiviral drug 88 . However, neuronglia interactions mediated by CXCL12 and CXCR4 in the spinal cord remain to be investigated. In addition, partial sciatic nerve injury induces a drastic upregulation of CCL3 (also known as MIP1α) in macrophages and Schwann cells of the injured sciatic nerve, and thermal hyperalgesia induced by nerve injury in mice was prevented by perineural treatment with small interfering RNA (siRNA) against the CCL3 receptor CCR5 (REF. 89 ). Nerve injury causes a persistent spinal upregulation of CCL3 and CCR5; furthermore, spinal and oral administration of the CCR5 antagonist maraviroc (Selzentry/Celsentri; Pfizer) alleviated neuropathic pain in rodents 90 .
Benefits and limitations of targeting chemokine signalling.
Although two chemokine receptor inhibitors are approved for clinical use, the CCR5 antagonist maraviroc for the treatment of HIV-1 infection and the anticancer CXCR4 antagonist plerixafor 91 , many chemokine receptor inhibitors have failed to show efficacy in clinical trials. Given the effectiveness of intrathecal and oral administration of maraviroc in a rodent model of neuropathic pain 90 , it will be interesting to test this drug in human pain conditions in the future. CCR2 is probably the most studied chemokine receptor in pain research 40, 77, 92 . AZD2423, which is a highly selective antagonist for CCR2, induced robust analgesia in two rodent models of neuropathic pain and a model of joint destruction pain (see the document entitled "NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules" on the American Psychological Association website for further information). However, AZD2423 did not show statistically significant effects in a trial of post-traumatic neuralgia, despite showing a trend towards a reduction in some sensory com ponents of pain, such as paroxysmal pain, paraesthesia and dysesthesia 93 . This low efficacy may arise from species selectivity (rodents versus humans), pharmacokinetic properties and/or drug metabolism, and redundancy in the chemokine network, as one chemokine often has more than one receptor. Given the important role of central chemokine signalling in chronic pain 23 , the low efficacy of the CCR2 antagonist AZD2423 in a clinical trial of pain 93 may also be due to poor CNS actions. To potentially increase the efficacy of chemokine antagonism, it might be beneficial to simultaneously target several chemokine receptors. Indeed the dual CCR2 and CCR5 peptide antagonist RAP-103 (which was orally active) effectively reduced neuropathic pain and inhibited CCR2-and CCR5-mediated monocyte chemotaxis and inflammation in rodents 94 .
Several CXCR2 antagonists have been tested in human models of inflammation [95] [96] [97] . Administration of AZD-8309, a pyrimidine-based CXCR2 antagonist, reduced neutrophil recruitment and leukotriene B 4 levels by 50% in a lipopolysaccharide-induced human airway inflammation model without causing systemic inflammation 95 . SB-656933, a selective and reversible CXCR2 antagonist, inhibited neutrophil activation in a dose-dependent manner and reduced ozone-induced airway inflammation following oral administration 96 . SCH527123, another selective antagonist of CXCR2, also attenuated ozone-induced airway neutrophil activation in healthy individuals 97 . Further preclinical studies are warranted to test these novel CXCR2 antagonists in animal models of Nature Reviews | Drug Discovery inflammatory and neuropathic pain. Given that CXCL1-CXCR2 signalling has a crucial role in the maintenance of chronic pain 55 , CXCR2 inhibitors or CNS-permeable antagonists could be promising for pain management.
Emerging targets: pro-resolution lipid mediators
Targeting lipid mediators that promote the resolution of inflammation could be another way of combating neuroinflammation. Notably, such lipid mediators -which include resolvins and protectins -not only act on immune cells and glial cells but also act on neurons and have neuroprotective actions [98] [99] [100] (TABLE 1) . Although the omega-3 unsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), which are metabolized to produce resolvins and protectins (FIG. 3) , have several benefits, including pain relief, when they are used experimentally the analgesic efficacy and potency of resolvins and protectins are much higher 101 .
Resolvins -such as resolvin D1 (RvD1), RvD2 and RvE1 -and protectin D1 represent a class of proresolution lipid mediators (PRLMs) 102 (FIG. 3) . Resolvins were originally isolated from inflammatory exudates that were involved in the resolution of inflammation in rodents and humans 102, 103 , and they have shown potent anti-inflammatory and pro-resolution effects in several rodent models of inflammation, such as colitis 104 , pneumonia and acute lung injury 105 , and kidney ischaemia 106 . Protectin D1 is also termed neuroprotectin D1 because it protects against experimental brain damage, oxidative stress in retinal pigment epithelial cells and the accumulation of amyloid-β peptides in cultured human brain cells 108, 110, 111 . The complete stereochemistry of protectin D1 and the 10,17S-docosatriene structure were confirmed by total organic synthesis 112 . Notably, the enzymes responsible for the synthesis of resolvins and protectins, such as 5-lipoxygenase (5-LO), 12-LO, 15-LO and cyclooxygenase 2 (COX2), can be induced at the acute or resolution phases of inflammation 113 . Thus, the conversion of consumed (digested) fish oil (which comprises DHA and EPA) to resolvins and protectins relies on the activities of these enzymes 101 . The biological actions of these lipid mediators are mediated by G protein-coupled receptors (GPCRs). For example, the GPCR chemokine-like receptor 1 (CMKLR1; also known as chemerin receptor 23 (ChemR23)) was identified as an RvE1 receptor 114 , whereas GPR32 and lipoxin A4 receptor (LXA4R; also known as ALX or FPR2) were identified as receptors for RvD1 (REF. 115 ). However, specific GPCRs for RvD2 and protectin D1 are still under investigation. In the sections below, we discuss the actions of resolvins and protectin D1 in rodents, and their translational potential.
Inhibition of inflammatory pain. Peripheral (intraplantar) injection of RvD1 and RvE1 effectively prevented inflammatory pain and also reduced inflammation-induced paw oedema and the expression of pro-inflammatory cytokines and chemokines (TNF, IL-1β, IL-6 and CCL2) in mice 99 . Moreover, spinal administration of RvE1 very rapidly (in less than 15 minutes) inhibited persistent inflammatory pain, at effective doses that were around 100 times lower than that of morphine 99 . RvE1 and protectin D1 are powerful inhibitors of TNF signalling: hyperalgesia evoked by spinal TNF can be blocked by intrathecal administration of RvE1 or protectin D1 66, 99 , which further indicates the importance of PRLMs in modulating CNS functions.
Protection of neuropathic pain and neuropathy. Neuropathic pain is often resistant to treatments that are effective for inflammatory pain, such as opioids and NSAIDs [116] [117] [118] . Strikingly, perisurgical treatment with protectin D1 completely prevented mechanical allodynia (FIG. 4a) in a mouse model of neuropathic pain 98 , whereas RvE1 and glia-derived neurotrophic factor (GDNF) only transiently prevented this type of pain 98, [119] [120] [121] . Moreover, protectin D1 post-treatment via the spinal intrathecal route, 2 weeks after nerve injury, also reversed nerve injury-induced mechanical allodynia for several hours (FIG. 4b,c) and did not induce antinociceptive tolerance 98 . Notably, much higher doses of gabapentin -which is widely used to treat neuropathic pain -were needed to suppress mechanical allodynia (FIG. 4c) . Interestingly, protectin D1 pretreatment suppressed the expression of activating transcription factor 3 (ATF3) associated with axonal injury 122 (that is, neuropathy) in DRG neurons 98 , which shows that protectin D1 further protects primary sensory neurons against neuropathy induced by nerve injury.
Regulation of synaptic plasticity and neuroinflammation.
Given the importance of synaptic plasticity in the induction and maintenance of chronic pain 17 , compounds that block synaptic plasticity in the spinal cord have the potential to be powerful analgesics. One of the most effective mechanisms by which PRLMs resolve pain is through modulation of spinal cord synaptic plasticity 98 . RvE1, RvD2 and protectin D1 did not alter excitatory synaptic transmission in ex vivo spinal neurons of spinal cord slices under normal (that is, non-painful) conditions 66, 99, 123 , but they reversed the increases in excitatory synaptic transmission that were induced by inflammation, nerve injury or TNF treatment 66, 98, 99, 123 . Further studies to investigate whether these PRLMs also modulate inhibitory synaptic transmission are warranted. It is noteworthy that spinal administration of protectin D1 and RvD2 reversed long-term potentiation-a form of synaptic plasticity that, in the spinal cord, has been linked to the development of pain -in vivo 66, 123 . Furthermore, perisurgical treatment with protectin D1 at the injury site controlled neuroinflammation induced by nerve injury in the CNS (FIG. 4e-g ) and PNS 98 . Other PRLMs, such as resolvins, also inhibit neuroinflammation in rodent models: RvE1 inhibited neuropathic pain and microglial activation 121 , and RvD1 inhibited arthritic pain and the expression of nuclear factor-κB (NF-κB) and COX2, in the DRG and spinal cord of rats 124 .
Modulation of TRP channels. TRP ion channels such as TRPV1, TRPA1 and TRPV4 are expressed by nociceptor neurons and are involved in peripheral sensitization and the pathogenesis of chronic pain [125] [126] [127] . Lipid mediators can act as endogenous ligands to activate or inhibit TRP channels 128, 129 . For example, in native DRG neurons protectin D1 potently inhibits TPRV1 (with a half-maximal inhibitory concentration (IC 50 ) of 0.4 nM) through actions that are mediated by G i/o -coupled GPCRs 66 . Of interest, resolvins differently modulate TRP channels: RvD1 only inhibits TRPA1, and RvE1 only inhibits TRPV1, but RvD2 inhibits both TRPA1 and TRPV1 in DRG neurons 123 . RvD1 also inhibits TRPV3 and TRPV4 in heterologous cells 130 . Thus, PRLMs are potent endogenous inhibitors of TRP channels. Of interest, CMKLR1 is heavily colocalized with TRPV1 in DRG neurons 99 . TRP channels serve as key signal transduction integrators for several inflammatory mediators, and hyperactivity of TRPA1 and TRPV1 is a hallmark of peripheral sensitization 125 . So, it is likely that PRLMs resolve peripheral sensitization in part by normalizing the hyperactivity -induced by tissue injury -of TRP channels without blocking the basic functions of these channels.
Benefits and limitations of PRLMs as drug targets. As described above, PRLMs have several actions that could be beneficial for treating inflammatory and postoperative pain associated with arthritis, lower-back injury and surgery, as well as neuropathic pain associated with nerve injury. In addition to resolvins and protectin, the lipoxins -which are PRLMs that are derived from arachidonic acid -reduce inflammatory pain in rats 3 . Maresin (macro phage mediator in resolving inflammation), derived from DHA, was also shown to prevent chemotherapy-induced neuropathic pain in mice 131 . The most striking benefits of these PRLMs are their high potency, a wide safety window and multiple mechanisms of action. These actions include the control of inflammation in peripheral tissues, control of neuroinflammation in the PNS and CNS, resolution of synaptic plasticity in the CNS, and modulation of TRP channel activities.
Current treatments for inflammatory and neuropathic pain are limited by well-known side effects. Opioids produce respiratory depression and sedation after acute treatment and also cause addiction, tolerance and hyperalgesia after chronic treatment. COX2 inhibitors are limited by cardiovascular defects after long-term treatment, and TNF-targeted treatment may cause infection through immunosuppression 101 . Neuropathic pain treatments such as gabapentin and pregabalin (Lyrica; Pfizer) are only effective in some patients and cause dizziness, drowsiness and nausea 132 . To overcome the disadvantages of current pain medicines, the endogenous PRLMs or their analogues could be developed for treating inflammatory pain 133 . Notably, despite aggressive preventive efforts 134 the incidence of developing chronic neuropathic pain after major surgeries, such as amputation, thoracotomy and breast surgeries, is very high 116 . Given the remarkable efficacy of protectin D1 in preventing neuropathic pain induced by nerve injury 98 , protectin D1 and their mimetics could be useful for the prevention of surgery-induced neuropathic pain. As post-treatment of protectin D1 via repeated injections does not cause analgesic tolerance and side effects under such a low dose 98 (FIG. 4) , protectin D1 and its analogues might also 
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be used to treat chronic neuropathic pain after diabetic neuropathy 98 and perhaps viral infection or chemotherapy, but further testing in animal models is needed.
PRLMs also have limitations as new therapeutics. It is well known that endogenous locally acting lipid mediators are metabolically unstable in vivo. For example, RvE1 reduces complete Freund's adjuvant (CFA)-induced heat hyperalgesia for less than 2 hours. However, a modified form of RvE1 (19-pf-RvE1), which is metabolically stable and resistant to local rapid metabolic inactivation, is able to reduce heat hyperalgesia for more than 6 hours 99 . Hence, the development of more stable forms of PRLMs (through chemical modification to enhance their halflives in body fluids), or improved delivery methods for unstable PRLMs (for example, using nanoparticles for sustained release of PRLMs) should prolong and enhance the analgesic effects of resolvins. The receptors for some PRLMs, such as CMKLR1 for RvE1 and LXA4R for RvD1, are widely expressed in neurons, glia and immune cells 3, [99] [100] [101] , which may explain the broad beneficial actions of PRLMs. However, the receptors for the other PRLMs (for example, protectin D1 and RvD2) and the detailed signalling mechanisms of how PRLMs resolve pain remain unclear. The identification of novel receptors (which are presumably GPCRs) and a better understanding of their signalling mechanisms will be crucial for the future development of small-molecule agonists for activating PRLM receptors and signalling pathways.
An alternative strategy is to boost the production of endogenous PRLMs through a healthy diet that is high in omega-3 fatty acids and low in omega-6 fatty acids. Effective conversion of dietary DHA and EPA to PRLMs may be responsible for the dietary control of chronic headaches 135 . Notably, aspirin initiates the biosynthetic pathway of RvE1 by acetylating COX2, which may explain the beneficial effects of low-dose aspirin in inflammation-associated chronic diseases 136, 137 . It will be of great interest to investigate whether diet control together with low-dose aspirin is a safe and low-cost treatment for certain types of chronic pain.
Other emerging targets for neuroinflammation Proteases. Increasing evidence suggests that proteases such as matrix metalloproteinases (MMPs) 138 , cathepsin S 73, 139 and caspases 48 are involved in pain sensitization by regulating neuroinflammation in the CNS. The MMP family has over 26 family members, of which the gelatinases MMP9 and MMP2 are among the most studied. Nerve injury induces a transient upregulation of MMP9 in DRG neurons in a mouse model; this transient upregulation is required for the induction -but not the maintenance -of neuropathic pain by inducing spinal cord microglial activation 138 . The maintenance of murine neuropathic pain is dependent on the delayed but persistent upregulation of MMP2 in DRG satellite cells and spinal cord astrocytes 138 . MMP9 is both sufficient and required for eliciting persistent mechanical allodynia via IL-1β signalling in mice 138 . Moreover, there is evidence that MMP levels are altered in human pain states, as MMP2 levels are upregulated in the cerebrospinal fluid of elderly patients with chronic osteoarthritis pain 140 .
Thus, inhibition of MMP9 could be used to prevent neuropathic pain after major surgeries (for example amputation and thoracotomy), spinal cord injury and brain trauma. Inhibition of MMP2 could have the potential to treat established neuropathic pain after diabetes, viral infection and chemotherapy. A dual inhibitor of MMP9 and MMP2 may help to treat neuropathic pain at different phases. Specific targeting of MMP9 and/or MMP2 can be achieved with small-molecule inhibitors, monoclonal antibodies and via the administration of endogenous inhibitors such as tissue inhibitor of MMP1 (TIMP1) and TIMP2 (REF. 138 ). Indeed, small-molecule inhibitors of MMP9 (termed MMP9 inhibitor I) and MMP2 (termed MMP2 inhibitor III), as well as TIMP1 and TIMP2, are effective in reducing murine neuropathic pain 138 . The thermal and tactile hypersensitivity induced by peripheral inflammation was also attenuated by intrathecal pretreatment with either an MMP3 inhibitor (N-isobutyl-N-(4-methoxyphenylsulphonyl)glycyl hydroxamic acid (NNGH)) or by a broad-spectrum MMP inhibitor (GM6001) 141 . However, MMPs also have normal physiological functions, and so broad inhibition of MMPs or long-term treatment of MMP2 and/or MMP9 inhibitors may cause undesirable side effects. For example, treating rodents with MMP inhibitors 7 days after stroke was shown to suppress neurovascular remodelling and increase ischaemic brain injury at 14 days The lysosomal cysteine protease cathepsin S has an important role in regulating neuron-microglia interactions in the spinal cord in neuropathic pain. After nerve injury, cathepsin S is upregulated in spinal microglia and contributes to the maintenance of neuropathic pain via cleavage of the transmembrane chemokine from the surface of DRG and spinal cord neurons. Activitydependent secretion of soluble CX3CL1 then activates microglia activation in the spinal cord 73, 147 . Intrathecal injection of the cathepsin S inhibitor morpholinurealeucine-homophenylalanine-vinyl phenyl sulphone (LHVS) reduced neuropathic pain in a mouse model 73 .
A recent study has shown that caspase 6 also regulates neuron-microglia signalling and activity-dependent central sensitization in the spinal cord 48 . Following tissue injury and nociceptive activity, release of caspase 6 from the central axonal terminals in the superficial dorsal horn causes TNF secretion from microglia to drive inflammatory pain 48 . Intrathecal injection of the caspase 6 inhibitor Z-Val-Glu(OMe)-Ile-Asp(OMe)-fluoromethylketone reduced murine inflammatory pain 48 . Thus, targeting cathepsin S and caspase 6 -first by identifying smallmolecule inhibitors -in the CNS may open up a new avenue for developing pain therapeutics.
WNT signalling. New evidence suggests that the WNT signalling pathway regulates neuroinflammation to promote chronic pain 148 . WNTs are a family of secreted signalling molecules that regulate several cellular processes, including proliferation, differentiation and migration, during the development of the nervous system. WNT ligands bind to Frizzled receptors and co-receptors and signal through canonical β-catenin-dependent pathways and non-canonical β-catenin-independent pathways. Dysregulation of WNT signalling is implicated in various neurological diseases 149 . Recent studies in rodents have demonstrated a crucial role of WNT signalling in the pathogenesis of neuropathic pain and cancer pain 148, 149 . Nerve injury and bone cancer caused rapid and longlasting upregulation of WNTs (such as WNT3A, a prototypical WNT ligand for the canonical pathway), as well as activation of WNT-Frizzled-β-catenin signalling, not only in primary sensory and spinal dorsal horn neurons but also in spinal astrocytes 148 . Spinal injection of inhibitors of WNT signalling pathways into rodents (for example, the WNT production inhibitor IWP-2 and WNT scavenger FZD8-Fc) attenuated the development and maintenance of neuropathic and cancer pain, and further blocked neuroinflammation induced by nerve injury (as measured by the expression of ionized calcium-binding adaptor molecule 1 (IBA1; also known as AIF1), glial fibrillary acidic protein (GFAP), IL-18 and TNF) in the spinal cord through the β-catenin pathway 148 . WNT signalling has also been implicated in the development of neuropathic pain after multiple sclerosis. WNT3A and β-catenin are upregulated in the spinal cord dorsal horn of mice with experimental autoimmune encephalomyelitis (EAE); inhibition of WNT5A (using the antagonist Box-5 (WNT5A-derived N-butyloxycarbonyl hexapeptide)) and β-catenin (using indomethacin) attenuated mechanical allodynia in mice with EAE 150 . Moreover, WNT ligands and downstream effector proteins are upregulated in the spinal cord dorsal horn of patients with HIV who develop pain but not in those who do not develop pain 151 . WNT signalling has been shown to regulate synaptic plasticity 152 and indeed may do so in chronic pain.
Phase I/II trials of inhibitors that target WNT ligand secretion or recognition, or downstream β-catenin function, have been initiated for cancer treatment (ClinicalTrials.gov identifiers: NCT01345201, NCT01608867, NCT01606579, NCT01302405 and NCT01351103). Side effects are the major limitation of these inhibitors, as other cells that have a high turnover rate also heavily rely on the WNT pathway for growth. However, if these inhibitors are proven to be safe they could be potentially used to treat chronic pain, and would be particularly attractive for treating cancer pain, as both pain and tumour growth could be targeted by the same molecule.
Concluding remarks
Current analgesics focus on reducing pain transduction and transmission in neurons, which explains their limited success in controlling disease progression 31, 153 . Mounting evidence suggests that neuroinflammation, as characterized by the activation of glial cells, infiltration of leukocytes and the production of inflammatory mediators, has a crucial role in the pathogenesis of chronic pain. Chronic pain is regarded as a consequence of 'gliopathy' -that is, dysfunction of glial cells 31 . Neuroinflammation drives chronic pain via neuronglia and neuron-immune cell interactions. We have reviewed the evidence that chemokines (CXCL1, CCL2 and CX3CL1), proteases (MMP9, cathepsin S and caspase 6) and the WNT signalling pathway contribute to neuroinflammation and chronic pain sensitization by regulating neuron-glia or glia-neuron interactions in the spinal cord. Thus, inhibitors of these emerging targets will uncover new avenues for the development of pain therapeutics.
In the past decade, the development of novel pain therapeutics has been disappointing 154 . The failures could be due to the complexity of chronic pain mechanisms (peripheral and central, neuronal and non-neuronal), a translational gap from animals to humans (it is a problem to solely rely on evoked reflex behaviour for pain measurement in animal models) 155, 156 and inadequate engagement of the claimed drug targets. A recent analysis of 44 Phase II trial decisions shows that the failures are not only caused by lack of efficacy but also, in a large number of cases (43%), by the fact that the mechanisms of action of drugs cannot be adequately tested at appropriate sites 157 . Given the fact that chronic pain is operated by distinct mechanisms at different phases, alternative strategies should also be considered for treating pain at early and late phases.
It has to be kept in mind that blocking the proinflammatory signalling of chemokines and proteases can have detrimental effects as well as beneficial effects. Inhibiting the immune response following bacterial or viral infections can be dangerous. Blocking proinflammatory signalling (for example, MMP9) in the late recovery phase of brain injury was shown to impair the resolution of neuroinflammation 142 . Acute neuroinflammation not only produces pro-inflammatory mediators but also recruits anti-inflammatory M2 macrophages 27 and generates anti-inflammatory and pro-resolution mediators for the resolution of neuroinflammation and pain (FIG. 2) . The PRLMs resolvins, protectins and lipoxins possess potent anti-inflammatory and antinociceptive actions by acting on neurons, immune cells and glial cells. Notably, these PRLMs are not immune suppressants; rather, they protect against bacterial and viral infection 158, 159 . Conceptually, PRLMs are different from classic analgesics as they do not alter basal pain perception but normalize abnormal pain 101 . Although PRLMs have several beneficial effects through multiple mechanisms of actions, their pharmacological properties as drugs need to be improved. One of the most effective treatments for these PRLMs (for example, protectin D1) is to prevent surgery-or trauma-induced chronic pain. Alternative strategies are to develop small-molecule agonists to stimulate their receptors and downstream signal transduction and also to boost endogenous production of these powerful lipid mediators through diet control together with low-dose aspirin.
Neuroinflammation is not only a driving force for chronic pain but also implicated in the majority of neurological, psychiatric and neurodevelopmental diseases 25, 160 . Given that chronic pain is a comorbidity of many of these diseases, targeting excessive neuroinflammation in the PNS and CNS without impairing the beneficial function of neuroinflammation will help to alleviate chronic pain and also control the progression of the underlying diseases.
